Single Rising Dose Study of BI 655066 in Patients With Moderate and Severe Psoriasis

Conditions

• Psoriasis

Interventions

• DRUG: BI 655066 (very high i.v. dose)
• DRUG: Placebo, i.v.
• DRUG: BI 655066 (high s.c. dose)
• DRUG: BI 655066 (low i.v. dose)
• DRUG: BI 655066 (high medium i.v. dose)
• DRUG: BI 655066 (very low i.v. dose)
• DRUG: BI 655066 (low s.c. dose)
• DRUG: BI 655066 (high i.v. dose)
• DRUG: Placebo, s.c.
• DRUG: BI 655066 (low medium i.v. dose)

Sponsor

AbbVie

Collaborators

• [object Object]